Wednesday, Johnson & Johnson (JNJ) announced its plan to settle most U.S. lawsuits related to its talc-based products and ovarian cancer. The company intends to pay a whopping $6.475 billion over 25 years to settle the ovarian cancer cases, which account for 99% of all talc-related lawsuits against J&J.

周三，强生公司宣布计划解决大多数与滑石产品和卵巢癌有关的美国诉讼。该公司计划在25年内支付高达64.75亿美元的费用来解决卵巢癌案件，这些案件占所有针对强生的滑石相关诉讼的99%。

Despite two previous unsuccessful efforts to resolve the lawsuits through its subsidiary's bankruptcy, J&J is now proposing to settle the claims through a third bankruptcy filing of its subsidiary, LLT Management LLC. This move aims to address all current and future ovarian cancer claims related to talc litigation in the U.S.

尽管之前两次通过其子公司破产解决诉讼的努力均未取得成功，但强生目前仍建议通过其子公司LLT Management LLC的第三次破产申请来解决索赔。此举旨在解决目前和未来所有与美国滑石粉诉讼有关的卵巢癌索赔。

To finalize the proposed settlement, 75% of claimants who allege harm from J&J's talcum products must agree to the deal. .

为了最终确定拟议的解决方案，75%声称强生滑石产品造成损害的索赔人必须同意该交易。

The proposed agreement will not only settle the ovarian cancer claims, but it will also expand J&J's existing settlements with individuals who sued the company for developing mesothelioma, a cancer linked to asbestos exposure, as well as settlements with various U.S. states for not warning consumers about the risks of its talc products.

拟议的协议不仅将解决卵巢癌索赔问题，还将扩大强生与起诉该公司发展间皮瘤（一种与石棉接触有关的癌症）的个人的现有和解，以及与美国各州的和解，因为他们没有警告消费者其滑石产品的风险。

The company has taken a charge of approximately $2.7 billion in the first quarter to bolster its reserve for talc claims to about $11 billion, highlighting the severity of the issue at hand. For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司在第一季度承担了约27亿美元的费用，将滑石粉索赔准备金增加到约110亿美元，突显了当前问题的严重性。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股